Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
158 hedge funds and large institutions have $1.53B invested in Revance Therapeutics, Inc. in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 55 increasing their positions, 44 reducing their positions, and 19 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 44
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less capital invested
Capital invested by funds: $1.6B → $1.53B (-$73.2M)
2% less funds holding
Funds holding: 161 → 158 (-3)
16% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 19
32% less call options, than puts
Call options by funds: $7.13M | Put options by funds: $10.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$21.5M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$16.8M |
| 3 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$9.42M |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$7.91M |
| 5 |
BAMCO Inc
New York
|
+$7.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$44.3M |
| 2 |
EWM
Essex Woodlands Management
The Woodlands,
Texas
|
-$24.6M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$5.03M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$4.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.47M |
RVNC Hedge Fund Activity: Q3 2021 in Review
158 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2021, worth a combined $1.53B — down 4.6% from $1.6B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of RVNC and 16 opened new positions — a net loss of 3 holders — while 44 trimmed existing stakes and 55 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $21.5M. The largest seller was Wellington Management Group, cutting an estimated $44.3M.
- 158 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2021, down from 161 in Q2 2021.
- Funds reported $1.53B of Revance Therapeutics, Inc. stock for Q3 2021, down 4.6% quarter-over-quarter.
- 16 funds opened new Revance Therapeutics, Inc. positions in Q3 2021 and 19 closed out, a net change of -3 holders.
- The largest Revance Therapeutics, Inc. buyer in Q3 2021 was Point72 Asset Management, an estimated $21.5M added.
- The largest Revance Therapeutics, Inc. seller in Q3 2021 was Wellington Management Group, an estimated $44.3M sold.
Based on aggregated 13F filings for Q3 2021.